Matthew Lemer, MD
Urology · White Plains, NYNPI 1598717589
Payments from drug & device makers
Across 370 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endo Pharmaceuticals Inc.$1K
- Teleflex LLC$1K
- Astellas Pharma US Inc$1K
- AbbVie$851
- Pfizer$659
- Endo USA, Inc.$547
- plus $4K from 30 others
What the payments were for
- Food & beverage$9,576100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endo Pharmaceuticals Inc. | 53 | $1,197 |
| Teleflex LLC | 14 | $1,115 |
| Astellas Pharma US Inc | 51 | $1,023 |
| AbbVie(2 entities) | 37 | $851 |
| Pfizer | 28 | $659 |
| Endo USA, Inc. | 17 | $547 |
| Antares Pharma, Inc. | 25 | $475 |
| Immunitybio, Inc. | 9 | $390 |
| Ferring Pharmaceuticals Inc. | 13 | $384 |
| Bayer | 16 | $368 |
| Johnson & Johnson | 12 | $356 |
| Merck | 13 | $310 |
| Urogen Pharma, Inc. | 9 | $299 |
| Tolmar, Inc. | 8 | $189 |
| Myriad Genetic Laboratories, Inc. | 8 | $180 |
| Dendreon Pharmaceuticals LLC | 6 | $165 |
| Myovant Sciences Inc. | 5 | $122 |
| Progenics Pharmaceuticals, Inc. | 4 | $89 |
| Coloplast | 4 | $89 |
| 180 Medical, Inc. | 4 | $78 |
| Acerus Pharmaceuticals Corporation | 4 | $78 |
| Dentsply IH AB | 3 | $74 |
| Sumitomo Pharma America, Inc. | 3 | $70 |
| Amgen | 3 | $62 |
| Urovant Sciences Inc | 3 | $54 |
| Olympus America Inc. | 2 | $51 |
| Hollister Incorporated | 3 | $46 |
| Accord Healthcare, Inc. | 2 | $46 |
| Blue Earth Diagnostics | 2 | $41 |
| Halozyme Inc | 2 | $36 |
| Aytu Biopharma, Inc. | 2 | $31 |
| Dentsply IH Inc. | 1 | $28 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $20 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $16 |
| Boston Scientific | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,576 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 35 | $505,058 |
| MyrbetriqMirabegron | 168 | $129,955 |
| XgevaDenosumab | 23 | $74,162 |
| GemtesaVibegron | 42 | $42,763 |
| ElmironPentosan Polysulfate Sodium | 12 | $12,237 |
| Tadalafil | 158 | $11,880 |
| XyostedTestosterone Enanthate | 11 | $9,820 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 285 | $6,688 |
| Tamsulosin Hcl | 206 | $2,678 |
| Oxybutynin Chloride ErOxybutynin Chloride | 117 | $2,601 |
| Silodosin | 22 | $2,520 |
| Trospium Chloride ErTrospium Chloride | 19 | $2,385 |
| Testosterone | 29 | $1,826 |
| Amitriptyline Hcl | 175 | $1,808 |
| Testosterone Cypionate | 36 | $1,444 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,023 | $635,014203 claims |
| AmgenXgeva | $62 | $74,16223 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $70 | $42,76342 claims |
| Antares Pharma, Inc.Xyosted | $475 | $9,82011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.
Other urology in White Plains
- Christopher PieczonkaSyracuse$31.2M
- Guarionex DecastroNew York$5.7M
- Mitchell EfrosGarden City$4.2M
- James McKiernanNew York$4.1M
- William HuangNew York$3.9M
- Jed KaminetskyMiddle Village$3.5M
- Evan GoldfischerPoughkeepsie$3.1M
- Gennady BratslavskySyracuse$2.5M
- Ashutosh TewariNew York$2.5M
- Manish ViraNew Hyde Park$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.